Resources

• Date: 15/04/2024

Life Molecular Imaging Collaboration Agreement

15 April 2024, IXICO plc (AIM: IXI), London, UK, the medical imaging advanced analytics company delivering intelligent insights in neuroscience, today provides information on its agreement with Life Molecular Imaging (LMI) for the supply of LMI's Neuraceq® Amyloid PET tracer (Florbetaben-18F) for use in pharma-sponsored clinical trials.

• Category: Alzheimer's Disease, Multiple Sclerosis, MRI, White Matter Imaging, Neuroinflammation
• Date: 03/04/2024

Imeka Collaboration Agreement

3 April 2024, IXICO plc (AIM: IXI), the medical imaging advanced analytics company delivering intelligent insights in neuroscience, announces a collaboration agreement with IMEKA Solutions Inc. ("Imeka") to provide access to Imeka's suite of services for white matter1 imaging deployed in Alzheimer's Disease (AD) and Multiple Sclerosis (MS) clinical trials, amongst other CNS indications.

Multiple Sclerosis – Advancing treatment through imaging biomarkers

Association between regional volume change and clinical change in Huntington’s disease HD-ISS Stage 2 and Stage 3 participants

For HD-ISS Stage 2 and Stage 3 participants, whole-brain volume shows significant association with clinical change for all four clinical variables examined here. For caudate and putamen volume, the association depended on the clinical variable. Our results provide further evidence on the use of volume change as a surrogate endpoint.

A Deep Learning Framework For Clinical Trial Enrichment in Alzheimer’s Disease

The selection of participants at risk of cognitive decline in clinical trials, known as trial enrichment, increases the probability of trial success. It is estimated that by 2050, 153 million people worldwide will be living with a type of dementia. Hence, innovative trial recruitment strategies are necessary to accelerate treatment development.

Comparison of amyloid positivity and global cortical SUVR between black and white non-Hispanic participants in the GAP Bio-Hermes study

Summary: This poster shows our further investigation on the amyloid PET differences between Black and White participants in the GAP Bio-Hermes study and to better understand the relationship between Aβ+ status from visual read and quantitative SUVR.

Parkinson's Disease - The road ahead for imaging biomarkers

A convolutional neural network-based framework for imaging biomarkers in MS - white matter hyperintensity & brain region volumes

Summary: We developed and validated scalable and robust methods for automated volumetric analysis of brain white matter hyperintensities (T2 lesions) and regions of interest in multiple sclerosis.